CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed
CytoMed Therapeutics已收購了馬來西亞臍帶血銀行Cellsafe International的許可證和部分資產，交易條款未透露。
- The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units, and (iii) two freehold real estate properties totalling 189 square metres in which the operation is situated.
- This acquisition will expand CytoMed's strategy in cell therapies as it now has access to rare and precious naïve cord blood donated for research and development. There are abundant clinical publications and evidence that cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases. This new biotechnology arm will be undertaken through CytoMed's subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.
- 該收購包括（i）由馬來西亞衛生部頒發的臍帶血銀行許可證，（ii）超過12,000個臍帶血單位的冷凍設備，以及（iii）兩處總面積爲189平方米的永久產權房地產物業，其中設有運營中心。
- 這項收購將擴大CytoMed在電芯療法領域的策略，因爲現在它可以接觸用於研究和開發的稀有且珍貴的原生臍帶血樣本。有大量的臨床出版物和證據表明，臍帶血在再生醫學和衰老疾病領域（包括自身免疫疾病）提供了廣泛的機會。這項新的生物技術業務將通過CytoMed的子公司LongevityBank Pte Ltd進行。後者是IPSC Depository Sdn Bhd的控股公司，後者持有馬來西亞衛生部頒發的臍帶血銀行許可證。
資訊熱榜
更新時間